Physician profile
Nilda Herrera
NPI 1568978377
$8,089.41
in general payments reported to CMS, 2019-2025
26 companies · $2,139 in 2025
The $2,139 reported for 2025 was more than what 94% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,136 · 2022: $1,091 · 2023: $1,705 · 2024: $2,018 · 2025: $2,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,738 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,737.99 |
| Education | $124.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,715.58 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,229.03 | 2021-2025 | Xifaxan, Trulance |
| Intercept Pharmaceuticals, INC. | $757.88 | 2021-2025 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $558.28 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $512.87 | 2022-2025 | Ibsrela |
| Janssen Biotech, INC. | $462.45 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Ironwood Pharmaceuticals, INC | $412.93 | 2021-2025 | Linzess |
| Ipsen Biopharmaceuticals, INC | $379.03 | 2024-2025 | Iqirvo |
| Braintree Laboratories, INC. | $345.55 | 2021-2025 | Sutab, Suflave |
| Redhill Biopharma INC. | $336.29 | 2021-2025 | Talicia, Aemcolo, Movantik |
| Madrigal Pharmaceuticals | $312.18 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $175.31 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $152.21 | 2021-2025 | Eohilia, Entyvio |
| Aimmune Therapeutics, INC. | $141.78 | 2024-2025 | Zenpep |
| Lilly USA, LLC | $127.23 | 2023-2025 | Omvoh |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $108.28 | 2021-2023 | Zeposia |
| Exact Sciences Corporation | $66.06 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pfizer INC. | $62.38 | 2023-2025 | |
| Evoke Pharma, INC. | $55.17 | 2023-2024 | Gimoti |
| Merck Sharp & Dohme LLC | $43.47 | 2021-2024 | Dificid |
| Novo Nordisk INC | $37.79 | 2025 | Wegovy |
| Genzyme Corporation | $25.61 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.57 | 2023 | Cyltezo |
| Alfasigma USA, INC. | $20.74 | 2021 | |
| Qol Medical, LLC | $15.02 | 2024 | Sucraid |
| Vivus LLC | $12.72 | 2023 | Qsymia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nilda Herrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.